Scholarlink

Background <p>Squamous cell carcinoma (SCC) of the ovary is a rare disease. The disease is resistant to chemotherapy and has a poor prognosis. Optimal first-line treatment is unclear, to our knowledge there are only 05 cases report of SCC arising from mature cystic teratoma (SCC-MCT) treated with immunotherapy.</p> <p>Case presentation:</p> <p>We report the case of recurrent metastatic SCC-MCT, in 32-year-old female Arab patient who was treated with Nivolumab after immunohistochemistry showed a high combined positive score&#xa0;(CPS) of 45%. The disease progressed after an initial partial response and the patient succumbed to her disease.</p> Conclusion <p>The prognosis of SCC-MCT remains grim. Given the success of immunotherapy in multiple solid tumors, next generation sequencing can help guide selection of those patients who may most benefit from immune checkpoint inhibitors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Squamous Cell Carcinoma Arising from Mature Cystic Teratoma Treated by Immunotherapy: A Case Report

  • 期刊论文

  • 发表日期：

    2025年5月4日

查看全文
  • Aref Zribi,
  • Reem al Mazroui,
  • Asma Naz Nadaf,
  • Ikram A. Burney

摘要

Background

Squamous cell carcinoma (SCC) of the ovary is a rare disease. The disease is resistant to chemotherapy and has a poor prognosis. Optimal first-line treatment is unclear, to our knowledge there are only 05 cases report of SCC arising from mature cystic teratoma (SCC-MCT) treated with immunotherapy.

Case presentation:

We report the case of recurrent metastatic SCC-MCT, in 32-year-old female Arab patient who was treated with Nivolumab after immunohistochemistry showed a high combined positive score (CPS) of 45%. The disease progressed after an initial partial response and the patient succumbed to her disease.

Conclusion

The prognosis of SCC-MCT remains grim. Given the success of immunotherapy in multiple solid tumors, next generation sequencing can help guide selection of those patients who may most benefit from immune checkpoint inhibitors.